FN2 Earnings Intelligence
AbbVie Inc. financials
AbbVie Inc. (ABBV) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $9,746 | $9,201 | $12,814 | $5,524 | $5,229 | - | - |
| + Debt | $75,976 | $63,129 | $59,245 | - | $67,002 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $56,197 | $58,054 | $54,318 | $56,334 | $61,160 | $67,345.8 | $72,845.3 |
| % Growth | 22.7% | 3.3% | -6.4% | 3.7% | 8.6% | 10.1% | 8.2% |
| Gross Profit | $38,751 | $40,640 | $33,903 | $39,430 | $42,956 | - | - |
| % Margin | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% | - | - |
| EBITDA | $18,727 | $18,895 | $13,509 | $9,901 | $15,837 | - | - |
| % Margin | 33.3% | 32.5% | 24.9% | 17.6% | 25.9% | - | - |
| Net Income | $11,542 | $11,836 | $4,863 | $4,278 | $4,226 | - | - |
| % Margin | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% | - | - |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 | $14.05 | $16.44 |
| % Growth | 137.1% | 2.8% | -59.0% | -12.1% | -1.3% | 495.3% | 17.0% |
| Operating Cash Flow | $22,777 | $24,943 | $22,839 | $18,806 | $19,030 | - | - |
| CapEx | $787 | $695 | $777 | $974 | $1,214 | - | - |
| Free Cash Flow | $21,990 | $24,248 | $22,062 | $17,832 | $17,816 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $56,197 | $58,054 | $54,318 | $56,334 | $61,160 | $67,345.8 | $72,845.3 |
| Gross Profit | $38,751 | $40,640 | $33,903 | $39,430 | $42,956 | - | - |
| EBITDA | $18,727 | $18,895 | $13,509 | $9,901 | $15,837 | - | - |
| Net Income | $11,542 | $11,836 | $4,863 | $4,278 | $4,226 | - | - |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 | $14.05 | $16.44 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9,746 | $9,201 | $12,814 | $5,524 | $5,229 |
| Short-term Debt | $14 | $1 | $0 | - | $2,499 |
| Long-term Debt | $75,962 | $63,128 | $59,245 | $66,841 | $64,503 |
| Total Debt | $75,976 | $63,129 | $59,245 | - | $67,002 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $22,777 | $24,943 | $22,839 | $18,806 | $19,030 |
| Capital Expenditure | $787 | $695 | $777 | $974 | $1,214 |
| Free Cash Flow | $21,990 | $24,248 | $22,062 | $17,832 | $17,816 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 22.7% | 3.3% | -6.4% | 3.7% | 8.6% |
| Gross Margin | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| EBITDA Margin | 33.3% | 32.5% | 24.9% | 17.6% | 25.9% |
| Net Margin | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| FCF Margin | 39.1% | 41.8% | 40.6% | 31.7% | 29.1% |
| Diluted EPS Growth | 137.1% | 2.8% | -59.0% | -12.1% | -1.3% |